T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2801
Solid Biosciences
SLDB
$782M
| $198K | ﹤0.01% |
35,087
| – | – |
|
2802
American Vanguard Corp
AVD
$55.2M
| $197K | ﹤0.01% |
51,543
-21,166
| -29% | -$99K |
|
2803
Inogen
INGN
$142M
| $196K | ﹤0.01% |
29,028
-800
| -3% | -$6K |
|
|
BIOA
2804
BioAge Labs
BIOA
$324M
| $196K | ﹤0.01% |
14,808
+2,917
| +25% | +$25.9K |
|
2805
Beyond Meat
BYND
$144M
| $195K | ﹤0.01% |
7,926
+5,353
| +208% | +$223K |
|
2806
Compass Diversified
CODI
$846M
| $195K | ﹤0.01% |
40,453
+4,738
| +13% | +$29.9K |
|
2807
Krispy Kreme
DNUT
$501M
| $192K | ﹤0.01% |
47,672
+8,351
| +21% | +$33.1K |
|
|
NMAX
2808
Newsmax Inc
NMAX
$1.4B
| $191K | ﹤0.01% |
+24,674
| New | +$237K |
|
2809
Byrna Technologies
BYRN
$81.7M
| $190K | ﹤0.01% |
11,304
+1,660
| +17% | +$32.3K |
|
2810
Editas Medicine
EDIT
$396M
| $190K | ﹤0.01% |
92,397
+6,177
| +7% | +$17.8K |
|
2811
OrthoPediatrics
KIDS
$589M
| $190K | ﹤0.01% |
+10,642
| New | +$186K |
|
2812
Microvision
MVIS
$48.9M
| $190K | ﹤0.01% |
15,415
+282
| +2% | +$4.5K |
|
2813
Inseego
INSG
$61.7M
| $188K | ﹤0.01% |
18,237
| – | – |
|
|
SHOE
2814
Shoe Station Group
SHOE
$353M
| $188K | ﹤0.01% |
+11,108
| New | +$204K |
|
2815
Entravision Communication
EVC
$684M
| $187K | ﹤0.01% |
63,482
| – | – |
|
2816
Petco
WOOF
$650M
| $187K | ﹤0.01% |
66,312
| – | – |
|
2817
American Coastal Insurance
ACIC
$444M
| $186K | ﹤0.01% |
14,686
+2,432
| +20% | +$29.4K |
|
2818
Simulations Plus
SLP
$373M
| $186K | ﹤0.01% |
+10,192
| New | +$179K |
|
|
ABX
2819
Abacus Global Management
ABX
$811M
| $185K | ﹤0.01% |
21,605
| – | – |
|
|
LOVE
2820
LoveSac
LOVE
$219M
| $185K | ﹤0.01% |
12,520
| – | – |
|
2821
Bioventus
BVS
$943M
| $184K | ﹤0.01% |
24,648
| – | – |
|
2822
MeiraGTx Holdings
MGTX
$1.05B
| $182K | ﹤0.01% |
22,776
| – | – |
|
2823
Smith Douglas Homes
SDHC
$86.3M
| $182K | ﹤0.01% |
+10,800
| New | +$195K |
|
2824
Superior Group of Companies
SGC
$205M
| $182K | ﹤0.01% |
18,710
| – | – |
|
2825
Altimmune
ALT
$595M
| $181K | ﹤0.01% |
49,879
+8,386
| +20% | +$36.6K |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.